Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Updates on DREAMM-2

Sagar Lonial • 19 Jun 2020
EHA 2020
Multiple Myeloma Antibodies Belantamab mafodotin Carfilzomib Daratumumab Pomalidomide
DREAMM-2

Sagar Lonial, MD, of Winship Cancer Institute of Emory University, Atlanta, GA, gives an update on DREAMM-2, evaluating single-agent belantamab mafodotin in relapsed/refractory multiple myeloma. Furthermore, Dr Lonial highlights the 11-month duration of response seen in the 2.5mg/kg cohort. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Sagar Lonial

1:05
Real-world comparison of RVD vs D-RVD in newly diagnosed transplant-eligible multiple myeloma
Sagar Lonial • 9 Dec 2023
0:45
The addition of daratumumab to RVD deepens treatment responses in t(11;14) multiple myeloma
Sagar Lonial • 9 Dec 2023
1:06
DeRIVE trial update: DId vs DVd in newly diagnosed MM
Sagar Lonial • 9 Dec 2023
0:48
Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myeloma
Sagar Lonial • 7 Sep 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals